



For Immediate Release

January 26, 2023

Acuitas Therapeutics' President & CEO Named a National Winner in the EY Canadian Entrepreneur of the Year Program

Vancouver, B.C. – In recognition of his commitment to innovation and entrepreneurial spirit, Dr. Thomas Madden, President & CEO of Acuitas Therapeutics, has been named one of EY's 10 Canadian National Winners in their Entrepreneur of the Year program. Dr. Madden accepted the award during a live show where he appeared with 35 elite entrepreneurs from across Canada on January 26, 2023.

"I am incredibly honoured and humbled to have been selected as one of the 10 EY Canadian National Winners, even more so because of the depth and breadth of the talent and achievement of this year's cohort," said Dr. Madden. He added: "The life sciences sector in B.C. and across Canada has been built by entrepreneurs and dreamers – by people who never give up. I have often heard that the life of an entrepreneur can be an isolated one. That hasn't been my experience. Everyone on the Acuitas team shows up each day looking to improve our lipid nanoparticle delivery technology, to work with our partners in advancing human health through nucleic acid therapeutics, and to support and encourage one another. I share this award with all of them."

About Acuitas Therapeutics

Vancouver-based Acuitas Therapeutics (www.acuitastx.com) is a private biotechnology company specializing in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. Acuitas partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes, to advance nucleic acid therapeutics into clinical trials and the marketplace. The team works with global partners to develop new therapies to address unmet clinical needs based on the internationally recognized capabilities of its proprietary delivery technology. Acuitas Therapeutics' lipid nanoparticle technology is used in the Pfizer/BioNTech COVID-19 vaccine COMIRNATY®. The Acuitas team is currently working on therapeutics focused on addressing cancer, HIV/AIDS, tuberculosis, malaria, rabies and other serious diseases.

In 2022, the company's co-founders – Drs. Thomas Madden (who is President & CEO), Michael Hope and Pieter Cullis – received the Governor General's Innovation Award; Acuitas was named



Life Sciences BC's Company of the Year and won the Greater Vancouver Board of Trades' Business Growth Award; Dr. Madden was named a Pacific Winner in the EY Entrepreneur of the Year Award Program and he received BIOTECanada's Gold Leaf Award for Game Changing Industry Leadership; and Dr. Cullis won the Bloom Burton Award, the Canada Gairdner International Award and the Tang Prize.

-END-